ES2034893A1 - Procedimiento para la obtencion de nuevos pregna-1,4-diene-3,20-dione-16-17-acetal-21 esteres. - Google Patents

Procedimiento para la obtencion de nuevos pregna-1,4-diene-3,20-dione-16-17-acetal-21 esteres.

Info

Publication number
ES2034893A1
ES2034893A1 ES919101991A ES9101991A ES2034893A1 ES 2034893 A1 ES2034893 A1 ES 2034893A1 ES 919101991 A ES919101991 A ES 919101991A ES 9101991 A ES9101991 A ES 9101991A ES 2034893 A1 ES2034893 A1 ES 2034893A1
Authority
ES
Spain
Prior art keywords
image
preparation
diene3
pregna
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES919101991A
Other languages
English (en)
Other versions
ES2034893B1 (es
Inventor
Jose Calatayud
Jose Ramon Conde
Manuel Luna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Especialidades Latinas Medicamentos Universales SA
Original Assignee
Especialidades Latinas Medicamentos Universales SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Especialidades Latinas Medicamentos Universales SA filed Critical Especialidades Latinas Medicamentos Universales SA
Publication of ES2034893A1 publication Critical patent/ES2034893A1/es
Application granted granted Critical
Publication of ES2034893B1 publication Critical patent/ES2034893B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE NUEVOS PREGNA-1,4-DIENE-3,20-DIONE-16-17-ACETAL-21 ESTERES. ESTOS COMPUESTOS DE LA FORMULA FORMULA ESTAN EN LA FORMA DE UN EPIMERO R, UN EPIMERO S O UNA MEZCLA ESTEREO-ISOMERA DE LOS EPIMEROS R Y S, EN TERMINOS DE LA ORIENTACION DE LOS SUSTITUYENTES SOBRE EL ATOMO DE CARBONO EN LA POSICION 22, CONSISTIENDO EL PROCEDIMIENTO PARA SU OBTENCION EN HIDROLISIS-CETALIZACION.
ES9101991A 1990-09-07 1991-09-05 Procedimiento para la obtencion de nuevos pregna-1,4-diene-3,20-dione-16-17-acetal-21 esteres. Expired - Fee Related ES2034893B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (2)

Publication Number Publication Date
ES2034893A1 true ES2034893A1 (es) 1993-04-01
ES2034893B1 ES2034893B1 (es) 1994-01-01

Family

ID=24314964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101991A Expired - Fee Related ES2034893B1 (es) 1990-09-07 1991-09-05 Procedimiento para la obtencion de nuevos pregna-1,4-diene-3,20-dione-16-17-acetal-21 esteres.

Country Status (19)

Country Link
US (1) US5482934A (es)
JP (1) JP3292928B2 (es)
KR (1) KR100193085B1 (es)
AT (1) AT402930B (es)
AU (1) AU649472B2 (es)
BE (1) BE1005876A5 (es)
BR (1) BR1100860A (es)
CA (1) CA2050812C (es)
CH (1) CH683343A5 (es)
DE (2) DE122005000030I2 (es)
ES (1) ES2034893B1 (es)
FR (1) FR2666585B1 (es)
GB (1) GB2247680B (es)
GR (1) GR1001529B (es)
HK (1) HK1005881A1 (es)
IT (1) IT1251376B (es)
LU (2) LU88001A1 (es)
NL (2) NL194917C (es)
PT (1) PT98897B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY105368A (en) * 1990-03-02 1994-09-30 Glaxo Group Ltd Inhalation device.
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
AU683463B2 (en) * 1993-04-02 1997-11-13 Astrazeneca Ab New prednisolone derivates
PT749438E (pt) * 1994-03-09 2001-05-31 Byk Gulden Lomberg Chem Fab Novos compostos sililo e sua utilizacao
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CA2430196C (en) 2000-11-10 2010-01-26 Altana Pharma Ag Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-dihydroxy-pregna-1,4-dien-3,20-dion or its 21-isobutyrat by transketalisation
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2004019955A1 (en) 2002-08-30 2004-03-11 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
DE60323138D1 (de) 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
ES2350396T3 (es) * 2003-09-15 2011-01-21 Nycomed Gmbh Uso de ciclesonida para el tratamiento de enfermedades intestinales inflamatorias.
EP1670482B2 (en) * 2003-09-16 2022-06-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
EP1796679A1 (en) * 2004-09-10 2007-06-20 Altana Pharma AG Ciclesonide and syk inhibitor combination and methods of use thereof
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20100209508A1 (en) * 2005-06-14 2010-08-19 Corus Pharma, Inc. Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备***龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
AU2006286838C1 (en) * 2005-09-02 2013-05-02 Ferrer Internacional S.A. Nitrooxy derivatives of glucocorticoids
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CA2622640A1 (en) * 2005-11-02 2007-05-18 Sicor Inc. Improved process for the preparation of ciclesonide
JP2009526068A (ja) * 2006-02-08 2009-07-16 シコール インコーポレイティド シクレソニド結晶形
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (en) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
EP2069355A4 (en) 2006-07-19 2010-03-24 Astrazeneca Ab NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
JO2868B1 (en) 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
WO2008062450A2 (en) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Crystalline polymorphs of ciclesonide
WO2008035066A2 (en) * 2006-09-19 2008-03-27 Cipla Limited Processes for the preparation of ciclesonide and its crystal form
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
BRPI0721039A2 (pt) 2006-12-19 2014-07-29 Astrazeneca Ab " derivados de quinuclidinol como antagonistas de receptores muscarínicos ".
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2022796A1 (en) * 2007-08-07 2009-02-11 Nycomed GmbH Amorphous ciclesonide
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
WO2009112557A2 (en) * 2008-03-13 2009-09-17 Farmabios S.P.A. Process for the preparation of pregnane derivatives
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
JP2011520877A (ja) * 2008-05-13 2011-07-21 アストラゼネカ・アクチエボラーグ ムスカリン受容体アンタゴニストおよびβ２−アドレナリン受容体アゴニストを含む医薬品
DK2297106T3 (da) 2008-05-27 2014-10-06 Astrazeneca Ab Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
CA2754589C (en) 2009-03-09 2013-07-16 Mikasa Seiyaku Co., Ltd. Steroid compound
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
KR20120104975A (ko) 2009-10-01 2012-09-24 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
CN102740830A (zh) * 2009-12-23 2012-10-17 普西维达公司 缓释递送装置
WO2011093814A2 (en) 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
WO2011136752A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
AU2012296880A1 (en) 2011-08-18 2014-03-27 Astrazeneca Ab Pharmaceutical aerosol product for administration by oral or nasal inhalation
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013109212A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US20240218011A1 (en) * 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164636A2 (en) * 1984-06-11 1985-12-18 SICOR Società Italiana Corticosteroidi S.p.A. A process for the preparation of 16,17 acetals of pregnane derivatives and compounds obtained therefrom

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378110B (es) * 1972-05-19 1975-08-18 Bofors Ab
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164636A2 (en) * 1984-06-11 1985-12-18 SICOR Società Italiana Corticosteroidi S.p.A. A process for the preparation of 16,17 acetals of pregnane derivatives and compounds obtained therefrom

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACTA PHARM. SUEC. Vol.19, 1982, A.ThalÚn:"Epimers of budesonide and related corticosteroids". pag. 327-354. *Todo el documento* *
ACTA PHARM. SUEC. Vol.21, 1984, A. ThalÚn et al."Synthesis and pharmacological properties of some 16 alpha-hydroxyprednisolone and fluorinated 16 alpha-hydroxyprednisolones". pßg. 109-124. *Todo el documento* *

Also Published As

Publication number Publication date
BE1005876A5 (nl) 1994-02-22
GB2247680A (en) 1992-03-11
AT402930B (de) 1997-09-25
DE122005000030I1 (de) 2005-10-06
FR2666585A1 (fr) 1992-03-13
US5482934A (en) 1996-01-09
ITMI912296A0 (it) 1991-08-28
JP3292928B2 (ja) 2002-06-17
IT1251376B (it) 1995-05-09
NL300196I1 (nl) 2005-08-01
HK1005881A1 (en) 1999-01-29
GR910100353A (en) 1992-09-11
FR2666585B1 (fr) 1994-09-09
GR1001529B (el) 1994-03-31
CH683343A5 (de) 1994-02-28
DE122005000030I2 (de) 2007-12-06
KR920006365A (ko) 1992-04-27
DE4129535A1 (de) 1992-03-12
ES2034893B1 (es) 1994-01-01
ATA176991A (de) 1997-02-15
DE4129535C2 (de) 2001-03-15
NL9101472A (nl) 1992-04-01
AU649472B2 (en) 1994-05-26
LU88001A1 (fr) 1992-06-01
CA2050812C (en) 2003-07-29
BR1100860A (pt) 1999-08-31
AU8368691A (en) 1992-03-12
ITMI912296A1 (it) 1993-02-28
GB9118967D0 (en) 1991-10-23
NL194917C (nl) 2003-09-01
CA2050812A1 (en) 1992-03-08
JPH04257599A (ja) 1992-09-11
NL300196I2 (nl) 2005-10-03
GB2247680B (en) 1994-06-01
PT98897B (pt) 2000-10-31
LU91205I2 (fr) 2006-05-30
KR100193085B1 (ko) 1999-06-15
PT98897A (pt) 1992-07-31

Similar Documents

Publication Publication Date Title
ES2034893A1 (es) Procedimiento para la obtencion de nuevos pregna-1,4-diene-3,20-dione-16-17-acetal-21 esteres.
FI101883B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 19,11 -sillan käsittävien steroidien valmistamiseksi
ES8306164A1 (es) Un procedimiento de preparacion de derivados de 4-pregneno .
MY111702A (en) 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
ES8800261A1 (es) Un procedimiento para preparar esteres de acido androstano-17 b-carboxilico
ATE27817T1 (de) Phenylpiperazin-derivate und verfahren zu deren herstellung.
DK535384A (da) 1,3-dioxan-4-yl-alken- og alkansyrer, fremgangsmaader til fremstilling heraf og midler med indhold heraf
GB2005246A (en) beta -Lactam compounds and processes for their preparation
ES482581A1 (es) Procedimiento para la preparacion de 2-fenilamino-imidazoli-nas-(2) sustituidas.
HUT34478A (en) Process for producing hexahydro-pyrrolo/2.1-a/isoquinoline derivatives and pharmaceutical compositions containing them
CA2026278A1 (en) Use of Alkylphosphoric Acid Compounds for Combatting Psoriasis Disorders
ES8304973A1 (es) Un procedimiento para la preparacion de nuevos derivados de tiocarbapenem 3-sustituidos.
ATE2511T1 (de) Neue peptidamide und verfahren zu ihrer herstellung.
EP0546875A3 (en) New process for the preparation of 20-oxo, 17-alpha, 21-dihydroxy derivatives of pregnane and new intermediates thereof
ES8505656A1 (es) Procedimiento para la preparacion de quinolinonas-4
JPS51113890A (en) Method for preparing novel cephalosporins
GEP19971011B (en) process for production of Compounds for Combatting Psoriasis Disorders
JO1478B1 (en) Legacy of the new androstan-17 beta carboxylic acid
ES8704163A1 (es) Un procedimiento para preparar derivados de cefem.
IE832944L (en) 6ó-methylprednisolone derivative.
TH7733EX (th) กริซิโอลิค แอซิด โมโนเอสเทอร์การเตรียมและการใช้สารประกอบเหล่านี้

Legal Events

Date Code Title Description
PC2A Transfer of patent
PC2A Transfer of patent
PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20111209